Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TN-401 by Tenaya Therapeutics for Cardiomyopathy: Likelihood of Approval
TN-401 is under clinical development by Tenaya Therapeutics and currently in Phase I for Cardiomyopathy. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-401?
TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-401?
TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy. According to Globaldata,...